Want to see BHC full AI Analyst Report?
Segment Profit Breakdown
Details how profit or loss is allocated across segments after accounting for each segment’s costs, showing which parts of the business are net contributors and which consume resources. Helps spot where management can cut costs, reallocate investment, or consider divestitures to improve overall returns.Salix and Solta are the clear profit engines, delivering sustained quarter-to-quarter acceleration that supports management’s upbeat guidance; Solta’s jump is China-driven but carries near-term margin pressure from acquisition-related inventory costs. Bausch Lomb showed a material late‑2025 recovery adding upside volatility, while the Diversified portfolio remains a consistent drag. Key watch items: new tariffs, potential Xifaxan generic risk and the Medicaid/340B exit, any of which could erode Salix momentum and cash flow despite improving EBITDA and net-debt reduction.
Date | Salix | International | Solta Medical | Diversified | Bausch Lomb |
|---|---|---|---|---|---|
Jun 30, 2026 | $605.00M | $90.00M | $91.00M | $142.00M | $335.00M |
Mar 31, 2026 | $468.00M | $88.00M | $75.00M | $112.00M | $277.00M |
Dec 31, 2025 | $529.00M | $81.00M | $55.00M | $179.00M | $396.00M |
Sep 30, 2025 | $570.00M | $90.00M | $70.00M | $182.00M | $301.00M |
Jun 30, 2025 | $455.00M | $78.00M | $54.00M | $139.00M | $248.00M |
Mar 31, 2025 | $371.00M | $85.00M | $53.00M | $127.00M | $180.00M |
Dec 31, 2024 | $460.00M | $98.00M | $73.00M | $157.00M | $309.00M |
Sep 30, 2024 | $436.00M | $105.00M | $53.00M | $189.00M | $283.00M |
Jun 30, 2024 | $377.00M | $86.00M | $47.00M | $166.00M | $274.00M |
Mar 31, 2024 | $329.00M | $87.00M | $40.00M | $114.00M | $242.00M |